Online inquiry

IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11911MR)

This product GTTS-WQ11911MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CCR2 gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001123041.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 729230
UniProt ID P41597
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11911MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11246MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ6859MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ1194MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ9714MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ4430MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ12243MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ4697MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ12807MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMS721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW